A breakthrough seizure is a seizure that occurs in a patient with a known, previously controlled seizure disorder despite being on antiseizure medication (ASM) - i.e., a seizure "breaks through" an existing treatment regimen that was otherwise working.
Most common cause
The single most common cause of a breakthrough seizure is a subtherapeutic anticonvulsant drug level, most often due to medication noncompliance (missed or reduced doses) - Tintinalli's Emergency Medicine, p. 3465-3469.
Other recognized triggers/mechanisms
Altitude changes - epileptic patients on stable therapy can have a breakthrough seizure at altitude; standard seizure workup is warranted, and acetazolamide 125-250 mg twice daily may be used prophylactically in this setting - Rosen's Emergency Medicine.
Drug interactions or pharmacokinetic changes that lower effective ASM levels (e.g., altered absorption, enzyme induction/inhibition, illness, pregnancy).
Pharmacoresistance - ASM not reaching the epileptogenic zone (e.g., due to multidrug transporters pumping the drug out of neurons) or the drug target becoming less sensitive to the ASM.
Tolerance - established with chronic benzodiazepine use, and possibly with other ASMs.
Paradoxical seizure aggravation - some ASMs can actually worsen seizure control or provoke new seizure types (e.g., myoclonic/absence seizures) even at therapeutic levels - documented with carbamazepine, oxcarbazepine, phenytoin, tiagabine, gabapentin, vigabatrin, and even levetiracetam in some patients.
ASM-induced encephalopathy or sedation (e.g., valproate-induced encephalopathy) can also exacerbate seizures rather than control them.
Common non-pharmacologic triggers in clinical practice also include sleep deprivation, alcohol use/withdrawal, fever/illness, and significant stress, though the textbook emphasis here is on drug-level and pharmacologic causes.
(Bradley and Daroff's Neurology in Clinical Practice, p. 1592-1608)
Clinical work-up
When a breakthrough seizure occurs in a patient with known epilepsy:
Check a serum anticonvulsant drug level (a very low level strongly suggests noncompliance).
Routine repeat drug levels aren't otherwise necessary in stable patients - they're mainly indicated after a breakthrough seizure, and the new level is compared to the patient's prior baseline.
Additional labs (glucose, electrolytes, calcium, magnesium, toxicology, pregnancy test) are guided by clinical context, especially if the seizure history or presentation is unclear.
In short: it's a seizure happening despite ongoing antiseizure treatment, most often signaling a drug-level problem (usually nonadherence) but sometimes reflecting true pharmacoresistance, tolerance, or a paradoxical drug effect.
This is a shared conversation. Sign in to Orris to start your own chat.